NCT07196852 Redox Status and Exercise Training-induced Adaptations
| NCT ID | NCT07196852 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Thessaly |
| Condition | Overweight (BMI > 25) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-09-22 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-09-22 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Excess fat accumulation is a key feature of overweight and obesity that is mainly driven by nutrient overload and insufficient physical activity. White adipose tissue displays lipid overload and hypertrophy accompanied by macrophages infiltration, hypoxia, inflammation and excess production of reactive oxygen species (ROS). An inflammatory response and ROS production are also evident in other metabolism regulating tissues and organs such as skeletal muscle, liver, pancreas and hypothalamus, contributing to a chronic inflammatory state, redox status disturbances and metabolic complications. There is overwhelming evidence showing that adults with overweight/obesity exhibit lower glutathione (GSH) levels in blood erythrocytes, skeletal muscle cells and subcutaneous and visceral adipose tissue cells. GSH, a tripeptide consisting of the amino acids glutamate, cysteine and glycine, is the most abundant thiol-containing antioxidant in the human body and has been, recently, characterized as a novel therapeutic target for the treatment of numerous chronic diseases, due to its potent intracellular redox buffering capacity. Interestingly, lower GSH levels have been associated with diet-induced weight loss resistance, while enhancement of GSH levels through N-acetylcysteine (NAC) supplementation reduces markers of oxidative stress, inflammation, insulin resistance, hypertension, endothelia dysfunction and improves vitamin D metabolism. NAC is a thiol donor that elicits antioxidant effects by (i) directly scavenging ROS and (ii) providing reduced cysteine through deacetylation, which supports the biosynthesis of endogenous GSH via the activity of γ-glutamylcysteine synthase. The aim of this study is to investigate whether NAC supplementation can enhance the exercise training-induced improvements on physical fitness and metabolic health in adult men and women with overweight/obesity.
Eligibility Criteria
Inclusion Criteria: * BMI 25-35 kg/m2 * Free of musculoskeletal injuries * Free of chronic non-communicable diseases * Do not receive any drug therapy * Do not receive dietary supplements * Normal menstrual cycle (for females) * Non smokers Exclusion Criteria: * NAC intolerance * Bleeding disorders * Kidney disease * Asthma * Usage of blood thinners and/or angina medication
Contact & Investigator
Anastasia Rosvoglou, PhDc
PRINCIPAL INVESTIGATOR
University of Thessaly, Department of Physical Education and Sport Science
Frequently Asked Questions
Who can join the NCT07196852 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 45 Years, studying Overweight (BMI > 25). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07196852 currently recruiting?
Yes, NCT07196852 is actively recruiting participants. Contact the research team at ddraganidis@uth.gr for enrollment information.
Where is the NCT07196852 trial being conducted?
This trial is being conducted at Trikala, Greece.
Who is sponsoring the NCT07196852 clinical trial?
NCT07196852 is sponsored by University of Thessaly. The principal investigator is Anastasia Rosvoglou, PhDc at University of Thessaly, Department of Physical Education and Sport Science. The trial plans to enroll 60 participants.